Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.49 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2870382 | 0.90 | BTK (0.47) | BTKNTRK1NTRK2IGF1RFGFR1 | |
| SCHEMBL2865064 | 0.87 | BTK (0.50) | BTKNTRK1NTRK2IGF1RFGFR1 | |
| SCHEMBL2868573 | 0.85 | ADORA3 (0.39) | BTKNTRK1NTRK2IGF1RFGFR1 | |
| SCHEMBL2868721 | 0.85 | ADORA3 (0.45) | ADORA3ADORA1TDP2 | |
| SCHEMBL2862967 | 0.85 | ADORA3 (0.58) | ADORA3ADORA1TP53LMNAMAPT | |
| SCHEMBL2862123 | 0.84 | ALDH1A1 (0.44) | BTKNTRK1NTRK2IGF1RFGFR1 | |
| SCHEMBL2858978 | 0.82 | ADORA3 (0.60) | ADORA3ADORA1TP53LMNAMAPT | |
| SCHEMBL2868582 | 0.81 | ADORA3 (0.47) | NTRK1NTRK2IGF1RFGFR1ADORA3 | |
| SCHEMBL2870417 | 0.80 | PDGFRB (0.43) | FGFR1 | |
| SCHEMBL2865205 | 0.80 | ADORA3 (0.47) | ADORA3ADORA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7842701-B2 | Pyrazoloquinolone derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1719771-A1 | PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281963-A1 | Pyrazoloquinolone Derivative And Use Thereof | MAP3K20, MAP4K5, MAP4K3 | BTK 272/4885NTRK1 381/4885NTRK2 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.